Category Archives: Drug Side Effects

New York, NY (PRWEB) March 01, 2013 The birth control safety advocates at DrugRisk.com are alerting women using the IUD contraceptive Mirena of updated information on the site showing use of the devices dropped for the last part of 2012, as a court gets set to decide the fate of growing patient injury claims. The mission of DrugRisk is to improve consumer safety by providing the latest drug warnings, recalls, studies and legal news. Many visitors look for legal news to learn if other patients are having similar side effects and whether they need legal advice, explains DrugRisk representative Ryan Mayer. DrugRisk contains information showing the FDA has received more than 47,000 AERS adverse event reports for complications by patients using the Mirena IUD.* Of these, 5079 involved dislocation and 1421 involved device migration, which can damage the uterine wall or other organs.* Over 6% of patients required hospitalization or surgery. Now, the latest financial reports from Bayer indicate sales of Mirena dropped 14% in the 4th quarter of 2012, from $206 million to $177 million, compared to the previous year.** DrugRisk has discovered injury claims from patients may be growing as well. With the number of patients filing a … Continue reading →

Dallas, TX (PRWEB) March 01, 2013 The birth control safety advocates at DrugRisk.com are alerting those who have taken the oral contraceptives Yaz or Yasmin of new information added to the site which shows Bayer continues to compensate victims of blood clot-type injuries related to the drugs. The goal of DrugRisk is to improve patient safety through education of the latest drug warnings, recalls, studies and litigation news. Many visitors to the site are concerned over blood clot side effects and want to know if Bayer is still compensating victims, explains DrugRisk representative Ryan Mayer. The resource center contains studies from the British Medical Journal and FDA which warned birth control pills containing the hormone drospirenone, like Yaz and Yasmin, can increase the risk of blood clots, DVT and pulmonary embolism by as much as 74%.* Now, DrugRisk has obtained the latest financial information from Bayer, which shows the company faces as many as 13,600 total claims relating to Yaz side effects.** So far, they have spent approximately $1 billion to settle around 4,800 claims involving blood clot injuries like deep vein thrombosis (DVT) or Yaz pulmonary embolism.** The records also indicate Bayer will continue to evaluate blood clot claims … Continue reading →

Health Video - Drug Side Effects Health Class Video. Drug Side Effects. CREDITS Naomi Wuebker, Jake Burns, Alexis Harris By: Cat Meow … Continue reading →

New studies show unhealthy side effects associated with the world's most popular weight loss drug. Diet Doc offers a new diet plan that provides better results than popular over-the-counter drugs, but without the known side effects of said drugs. Charlotte, NC (PRWEB) February 26, 2013 The University of Rhode Island has discovered that Orlistat interferes with the natural detoxification process in the liver, kidneys and gastrointestinal tract by inhibiting a key enzyme known as carboxylesterase-2. The inhibition is irreversible and results in serious organ damage and severe toxicity. Diet Docs scientific approach to fast weight loss is responsible for the high success rate of their prescription hCG diets. Pharmaceutical grade hCG suppresses the appetite and also signals the body to use fat as a source of fuel. This hormone speeds up the process of fat metabolism at the cellular level to trigger fast weight loss even in tough areas such as the thighs, underarms, and stomach, without any documented side effects. According to Biochemical Pharmacology 2012, Orlistat that is available as an over-the-counter remedy in many pharmacies can cause damage even at low doses. Professor Bingfang Yans study funded by the NIH (National Institutes of Health) also shows that Orlistat … Continue reading →

Washington DC (PRWEB) February 28, 2013 The prescription drug resource site Drugrisks.com is alerting atrial fibrillation patients who take the blood thinner Pradaxa to prevent stroke of new information on the site which shows the maker of the drug has paid for a study which was just released disputing prior warnings over internal bleeding. The goal of Drugrisks is to improve consumer safety through education. By providing patients the latest drug warnings, recalls, studies and litigation news, they can discuss treatment options with their doctor and decide if they need legal advice. It is important to know whether new research is independent or funded by the company selling the drug, explains Drugrisks representative Ryan Mayer. Information on Drugrisks shows health experts still disagree about Pradaxas safety and bleeding risks. The FDA recently updated reports to indicate the drug carries the same risks as warfarin.* However, the American College of Cardiology has cautioned that Pradaxa can increase the risk of bleeding complications compared to warfarin.** The resource center also recently added a report from the Institute for Safe Medication Practices which ranks blood thinners like Pradaxa among the most dangerous drugs. The institute reviewed nearly 18,000 adverse events reported to the … Continue reading →

TUESDAY, Feb. 26 (HealthDay News) -- Combining the vitamin niacin with a cholesterol-lowering statin drug appears to raise side effects in heart patients, a new study indicates. Muscle, skin and gastrointestinal problems were among the side effects that caused one-quarter of patients to stop treatment in a study looking at whether the use of niacin in combination with a statin might reduce heart disease risk. Niacin has long been used to boost levels of "good" HDL cholesterol and decrease levels of "bad" LDL cholesterol and triglycerides (fats) in the blood in people at risk for heart disease and stroke. However, niacin also causes a number of side effects, including flushing of the skin. A drug called laropiprant can reduce the incidence of flushing in people taking niacin. This new study included nearly 26,000 patients with narrowing of the arteries. They received either 2 grams of extended-release niacin plus 40 milligrams of laropiprant or matching placebos. All of the patients also took the statin drug Zocor (simvastatin). The patients from China, the United Kingdom and Scandinavia were followed for an average of almost four years. By the end of the study, 25 percent of patients taking niacin plus laropiprant had stopped … Continue reading →

NEW YORK (Reuters Health) - One-quarter of people taking niacin and statins as part of a four-year-long heart study dropped out early, often for medical reasons tied to niacin's side effects, a new study suggests. Previous research hinted that niacin could boost HDL ("good") cholesterol levels, but it was unclear whether the B-vitamin would improve heart health. The full data from the new study, which included 25,000 people in Europe and China, are being presented next month at the American College of Cardiology annual meeting in San Francisco. The trial already led Merck to pull its niacin-based cholesterol drug Tredaptive from the market last month, when it was determined that its heart-related benefits didn't outweigh its risks. The current analysis details participants' side effects and reasons for leaving that trial, and finds that itching and rashes, indigestion and muscle problems were all common among those taking the niacin-statin combination. "There's been a lot of interest in trying to find therapies to raise HDL," said Dr. Erin Michos, a cardiologist at the Johns Hopkins School of Medicine in Baltimore. "Unfortunately I think there's a growing body of evidence that's going to put the nail in the coffin for niacin," Michos, who … Continue reading →

BRENTFORD, UK (TheStreet) -- Duchenne muscular dystrophy patients treated with GlaxoSmithKline's (GSK) experimental drug drisapersen have been hospitalized due to kidney toxicity and low platelet counts, according to a Glaxo scientist who spoke at a research meeting in Rome last Sunday. Glaxo has disclosed some safety data from early-stage drisapersen clinical trials previously, mainly related to moderate cases of proteinuria (excess protein in the urine) and decreased thrombocytes, which play a role in blood clotting. However, the significance of the adverse events attributed to drisapersen, also known as GSK-2402968, escalated with Sunday's disclosure of hospitalized patients. Dr. Rohit Batta, global medical leader in Glaxo's neuromuscular rare disease unit, said four Duchenne muscular dystrophy (DMD) patients treated with drisapersen required hospitalization due to thrombocytopenia and that "several" patients with "severe proteinuria" also required hospitalization. See if (GSK) is in our portfolio Batta's remarks were made during a presentation on Sunday, Feb. 24 at The XI International Conference on Duchenne Muscular Dystrophy. The conference was held in Rome and organized by Duchenne Parent Project Onlus, an Italian DMD advocacy group. Read more here: Glaxo DMD Drug Tied to Serious Side Effects, Hospitalizations … Continue reading →

New York, NY (PRWEB) February 27, 2013 The birth control safety advocates at DrugRisk.com are alerting women who have suffered side effects while using the IUD contraceptive Mirena of legal updates that could affect how and where hundreds of injury claims are handled. DrugRisks mission is to improve patient safety by providing the latest drug warnings, recalls, studies and legal news. Not only can patients use information to discuss options with their doctor, they can see others experiences and decide if they need legal advice, explains DrugRisk representative Ryan Mayer. DrugRisk has added the latest FDA AERS updates showing more than 47,000 patients have reported complications from the Mirena IUD.* Of these, 5079 involved dislocation and 1421 involved device migration, which can damage the uterine wall or other organs.* Over 6% of patients required hospitalization or Mirena removal via surgery. The resource center has also learned that the FDA already warned Bayer about the marketing of Mirena in 2009, after they failed to disclose safety risks.** With the number of patients filing a Mirena lawsuit increasing, plaintiffs filed a request that cases be consolidated to a special federal Multi-District Litigation court in Ohio.*** The petition estimates that, with more than … Continue reading →

Dallas, TX (PRWEB) February 27, 2013 The prescription drug resource center DrugRisk.com is alerting diabetes patients of updated news added to the site drug maker Takeda Pharmaceuticals, who makes Actos, is set to launch a new diabetes medication as they face as many as 3,000 lawsuits alleging Actos caused bladder cancer. DrugRisks goal is to improve patient safety through education. By providing the latest drug warnings, recalls, studies and litigation news, patients can discuss options with their doctor and decide if they need legal advice, explains DrugRisk representative Ryan Mayer. The resource center contains Actos warnings from both the FDA* and European Medicines Agency** who indicated that long-term use of the drug may be associated with an increased risk of Actos bladder cancer. The drug has also been banned in France and Germany.*** In legal news, DrugRisk has learned that Takeda faces as many as 3,000 claims over Actos bladder cancer.**** More than 1,200 patients have filed an Actos lawsuit against the drug maker in a special multi-district federal court in Louisiana.***** Another group of cases were scheduled to start last week in California.**** Now, with the growing legal action and the patent on Actos expiring last year, Takeda has … Continue reading →